Apogenix AG Email Format
Biotechnology ResearchBaden-württemberg, Germany51-200 Employees
Apogenix AG is a Heidelberg-based biotechnology company focused on immunotherapy research for cancer and viral infections, including COVID-19. It pursues a pipeline of drug candidates that influence TNFSF-dependent signaling pathways to modulate immune responses. The aim is to reduce lymphopenia and inflammatory cell death in viral infections while restoring anti-tumor immunity in cancer patients. With a mid-sized team, the company operates within the biotechnology research sector to advance targeted immunotherapies. A notable development is the 2020 introduction of a CD95 ligand inhibitor, asunercept, marking a concrete step in its program for severe disease in cancer and viral contexts. The company has previously partnered to develop companion diagnostic tests for its lead product APG101, illustrating an integrated therapy approach.